Enzyme Developed from Corn can Reduce Cost of Treating Life-Threatening Inherited Disease

Canadian biologists revealed that they have developed a new medical enzyme through genetically engineered corn that could be used to reduce the cost of treating a life-threatening inherited disease.

Inserting a section of DNA code into maize seed caused them to make alpha-L-iduronidase in the endosperm, a nutritive tissue in the corn kernel.

About Genetic Testing
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laboratory techniques

Alpha-L-iduronidase breaks down sugar molecules and is deficient in people with mucopolysaccheridosis I (MPS 1).

This is a so-called lysosomal storage disorder, in which sugary debris builds up in cells, damaging tissue in the heart, eyes, skeleton and brain.

Without replacement enzymes, sufferers of MPS 1 often die in childhood.

Epigenetics
In the recent years ‘epigenetics’ represents inheritable changes in gene expression that do not include DNA alterations.

Until now, the therapy has been produced by coaxing cultures of cells taken from the ovaries of Chinese hamsters, and is hugely expensive.

The existing drug for MPS 1, laronidase (marketed as Aldurazyme) costs around $300,000 annually for children and $1 million for adults.

Hemophilia - Causes - Treatment - Genetic Testing - Support Groups
Hemophilia is a rare single gene, X- linked disorder, which tends to run in families.

The research, led by Allison Kermode at Simon Fraser University in Burnaby, British Columbia, is published in the journal Nature Communications.

The results amount to "proof of concept" for making the enzyme in laboratory conditions, the team say.

Further work would be needed to scale up volume, but this should not be too much of a problem and conventional techniques could be used, they add.

Severe MPS I occurs in approximately in one in 100,000 newborns, according to the website Genetics Home Reference, which is supported by the US health authorities.

A milder form, called attenuated MPS I, occurs in about one in 500,000 births.

Source-AFP